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Summary Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus
replacement dose hydrocortisone. None of the 4 patients with intact testes responded, although 3 did so
subsequently to tamoxifen. The previously orchidetomised patient responded to amminoglutethimide for 14
months. Oestrone and oestradiol were suppressed by AG in all patients, but not to the levels achieved by
orchidectomy. AG produced substantial further oestrogen suppression in the orchidectomised patient and
should only be used after orchidectomy.
Breast cancer in males is an uncommon disease. It
accounts for 1% of all breast cancers and is fre-
quently sensitive to hormone manipulation (Ribeiro,
1985). Breast cancer in men presents at a more
advanced stage and in older age groups compared
with women, but when matched for these prog-
nostic variables, survival is similar (Scheike, 1982).
Because of these clinical features, systemic endo-
crine therapy is commonly combined with local
treatment, castration being a standard first line
endocrine approach.
Recently, aminoglutethimide has been shown to
be effective in postmenopausal women with breast
cancer, the main mechanism of action being inhi-
bition of the peripheral conversion of androgens to
oestrogens by aromatase (Harris et al., 1982a;
1983a). In men, three quarters of oestradiol
produced results from peripheral aromatisation of
testosterone (Epstein et al., 1966; Longcope et al.,
1969; Wu et al., 1982). Thus aminoglutethimide
could potentially be useful either to avoid castra-
tion or as a second line endocrine therapy to
suppress residual oestrogen production via
androgens from the adrenal after castration.
Patients and methods
Five men with advanced breast cancer were treated
with aminoglutethimide and replacement dose
hydrocortisone (20mg twice daily). Four patients
received the conventional dose of aminoglutethi-
mide, 250mg four times daily, and one received
125mg twice daily.
Plasma samples were taken before treatment and
at 2 weekly intervals for measurement of oestrone,
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oestradiol, testosterone and A4 androstenedione by
previously described assays (Harris et al., 1982a,b;
1983a, b).
Tumour response was assessed by standard
UICC criteria (Hayward et al., 1977).
Results
Clinical responses to aminoglutethimide and
hydrocortisone
The pretreatment characteristics are shown in
Table I. Only 1 patient had been orchidectomised. He
initially presented with secondary deposits in his
axilla and a pleural effusion. Initial treatment was
with orchidectomy plus chemotherapy with 5-
fluorouracil (5FU), methotrexate (MTX) and
vincristine (VCR) for eight courses. There was a
partial response. He relapsed in the axilla again a
year later and responded to ethinyloestradiol. After
3 years, a further local recurrence was excised. He
relapsed 12 months later in the lung and bone and
received aminoglutethimide. He responded to
aminoglutethimide for 14 months. There was no
response in the 4 patients with intact testes. This
was not due to hormone resistance, since three of
these patients responded very well to tamoxifen.
Responses to tamoxifen are shown in Figures 1
and 2.
Endocrine effects ofaminoglutethimide and
hydrocortisone
Oestrone and oestradiol levels were suppressed in
all patients (Figure 3). However, in only 1 patient
out of the 4 not orchidectomised, did oestrone fall
below the basal oestrone level in the castrate
patient. In none of the former 4 did oestradiol fall
below the basal level in the castrate patient. In the
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Figure 1 Response of lung secondaries to tamoxifen.
Patient no. 5. Progressive lung secondaries on amino-
glutethimide (a) tamoxifen response (b) film 7 months
later than (a).
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latter, basal oestrone and oestradiol levels were
further suppressed.
Testosterone and androstenedione were not sig-
nificantly affected.
Discussion
A high frequency of oestrogen receptor positive
tumours has been reported in male breast cancer,
85% in one series (Everson et al., 1980). Farrow
and Adair first reported a response to bilateral
orchidectomy and this has been a standard first-line
therapy. Recent series show a response rate of 32-
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Figure 2 Response of rib secondary to tamoxifen. Patient no. 2. Progressive 7th
aminoglutethimide (a). Tamoxifen response (b) film 4 months later than (a).
Oestradiol A4 Androstenedione
Oestrone Testosterone
pre 4 wk pre 4 wk pre 4 wk pre 4 wk
2 wk 2 wk 2 wk 2 wk
Figure 3 Endocrine effects of aminoglutethimide in
male patients with breast cancer. Each symbol repre-
sents a different patient. Samples were taken before
starting aminoglutethimide and at 2 weekly intervals.
0 O, orchidectomised patient (no. 1).
48% (Patel et al., 1984; Kraybill et al., 1981).
Castration removes both androgens and a major
source of oestrogen precursors so it is not clear
which is the major determinant of responses in
male breast cancer. However, tamoxifen also pro-
duces responses in men who have not been
castrated (25-66% response rate, Patterson et al.,
1980; Ribeiro, 1983), so antioestrogen effects are
important. Stilboestrol has been used as a first-line
therapy, but this will also suppress androgens
(Ribeiro, 1976).
Adrenalectomy removes adrenal androgens which
rib destruction on
are the main residual source of both androgens and
oestrogens after castration. Responses of 73-80%
(14/19, 8/10) have been reported, all as second line
after orchidectomy (Patel et al., 1984; Meyskens et
al., 1976).
Corticosteroids alone produced a response of
43% after orchidectomy, presumably by sup-
pressing residual adrenal androgen production and
hence removing a source of oestrogens (Kantarjian
et al., 1983).
The endocrine data show that aminoglutethimide
plus hydrocortisone suppresses peripheral oestrone
and oestradiol levels.
The lower dose of aminoglutethimide plus hydro-
cortisone produced as much oestrone and oestradiol
suppression as the conventional dose plus hydro-
cortisone. A similar effect ofconventional doses has
been shown in normal males (Santen et al., 1979).
However, this suppression was inadequate to
produce a therapeutic response. Basal oestradiol
levels in our series were in the same range as
reported by Nirmul et al. (1982). The patients were
not intrinsically resistant to endocrine therapy,
since 3 out of 4 responded to tamoxifen. Aminoglu-
tethimide did not suppress oestrogens to the level
obtained by orchidectomy, thus suggesting a dose-
response effect.
In the orchidectomised patient, a response was
obtained and residual oestrogen levels were sup-
pressed by more than 50%. There is one previous
case of effective therapy with aminoglutethimide
(Patel et al., 1984) after orchidectomy.
Although these results are only on a small
number of patients, they suggest that amino-
glutethimide plus hydrocortisone should not be used
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as a first-line therapy, that they are worth using
as a second line therapy after orchidectomy, and
that adequate oestrogen rather than androgen
suppression is important.
The lower dose of aminoglutethimide may be as
effective as higher, more toxic doses, but this will
require further evaluation.
The effectiveness of tamoxifen in patients who
had not been orchidectomised suggests this should
be first-line therapy in such patients.
References
EPSTEIN, B.J., RAHEJA, M.C., FROW, E. & MORSEL, W.J.
(1966) Estrogen synthesis in normal and hypogonadal
men. Can. J. Biochem., 44, 971.
EVERSON, R.B., LIPPMAN, M.E., THOMPSON, E.B. & 7
others (1980). Clinical correlations of steroid receptors
and male breast cancer. Cancer Res., 40, 991.
HARRIS, A.L., POWLES, T.J. & SMITH, I.E. (1982a).
Aminoglutethimide in the treatment of advanced
postmenopausal breast cancer. Cancer Res., 42, 3405S.
HARRIS, A.L., DOWSETT, M., JEFFCOATE, S.L.,
McKINNA, J.A., MORGAN, M. & SMITH, I.E. (1982b).
Endocrine and therapeutic effects of aminoglutethi-
mide in premenopausal patients with breast cancer. J.
Clin. Endocrinol. Metab., 55, 718.
HARRIS, A.L., DOWSETT, M., SMITH, I.E. & JEFFCOATE,
S.L. (1983a). Endocrine effects of low dose aminoglute-
thimide alone in advanced postmenopausal breast
cancer. Br. J. Cancer, 47, 621.
HARRIS, A.L., DOWSETT, M., JEFFCOATE, S.L. & SMITH,
I.E. (1983b). Aminogultethimide dose and hormone
suppression in advanced breast cancer. Eur. J. Cancer
Clin. Oncol., 19, 493.
HAYWARD, J.L., CARBONE, P.P., HEUSON, J.C.,
HUMAOKA, S., SEGALOFF, A. & RUBENS, R.D. (1977).
Assessment of response to therapy in advanced breast
cancer. Eur. J. Cancer, 13, 89.
KANTARJIAN, H., YAP, H.-Y., HORTOBAGYI, G.,
BUZDAR, A. & BLUMENSCHEIN, G. (1983). Hormonal
therapy for metastatic male breast cancer. Arch. Int.
Med., 143, 237.
KRAYBILL, W.G., KAUFMAN, R. & KINNE, D. (1981).
Treatment of advanced male breast cancer. Cancer, 47,
2185.
LONGCOPE, C., KATO, T. & HORTON, R. (1969).
Conversion of blood androgens to estrogens in normal
adult males and females. J. Clin. Invest., 48, 219.
MEYSKENS, F.L., TORMEY, D.C. & NEIFELD, J.P. (1976).
Male breast cancer, a review. Cancer Treat. Rev., 3,
83.
NIRMUL, D., PEGORARO, R.J., JIALAL, I, NAIDOO, C. &
JOUBERT, S.M. (1982). The sex hormone profile of
male patients with breast cancer. Br. J. Cancer, 48,
423.
PATEL, J.K., NEMOTO, T. & DAO, T.L. (1984). Metastatic
breast cancer in males. Assessment of endocrine
therapy. Cancer, 53, 1344.
PATTERSON, J.S., BATTERSBY, L.A. & BACH, B.K. (1980).
Use of tamoxifen in advanced male breast cancer.
Cancer Treat. Rep., 64, 801.
RIBEIRO, G.G. (1976). The results of diethylstilboestrol
therapy for recurrent and metastatic carcinoma of the
male breast. Br. J. Cancer, 33, 465.
RIBEIRO, G.G. (1983). Tamoxifen in the treatment of male
breast carcinoma. Clin. Radiol., 34, 625.
RIBEIRO, G.G. (1985). Male breast carcinoma, a review of
301 cases from the Christie Hospital and Holt Radium
Institute, Manchester. Br. J. Cancer, 51, 115.
SANTEN, R.J., COHN, N., MISBIN, R., SAMOJLIK, E. &
FOLTZ, E. (1979). Acute effects of aminoglutethimide
on testicular steroidogenesis in normal men. J. Clin.
Endocrinol. Metab., 49, 631.
SCHEIKE, 0. (1982). Factors provoking male breast
cancer. New aspects of breast cancer. In Risk Factors
in Breast Cancer, 2, Stoll, B.A. (ed.), p. 173. W.
Heinemann, London.
WU, F.C.W., SWANSTON, I.A., HARGREAVE, T.B. &
BAIRD, D.T. (1982). Human testis does not secrete
oestrone sulphate. J. Endocrinol, 92, 185.